|
業務類別
|
Biotechnology |
|
業務概覽
|
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis. |
| 公司地址
| 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 415 798-8589 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tempesttx.com |
| 員工數量
| 4 |
| Mr. Nicholas J. Rossettos,C.P.A. |
Chief Financial Officer, Treasurer, Principal Accounting Officer and Secretary |
-- |
24/08/2026 |
| Dr. Matthew Angel, PhD |
Director, President and Chief Executive Officer |
-- |
06/02/2026 |
|
|
| Mr. Stephen R. Brady |
Chairman of the Board |
24/08/2026 |
| Dr. John David Yee, M.D. |
Independent Director |
04/06/2026 |
| Dr. Matthew Angel, PhD |
Director, President and Chief Executive Officer |
06/02/2026 |
| Mr. William Drake Richey |
Independent Director |
04/06/2026 |
|
|
|
|
